Publication:
NOL4 is a novel nuclear marker of small cell carcinoma and other neuroendocrine neoplasms

Simple item page
dc.contributor.authorLee, Jung Hee
dc.contributor.authorShin, Dong Hoon
dc.contributor.authorLee, Sang Yull
dc.contributor.authorPark, Jun Young
dc.contributor.authorKim, So Young
dc.contributor.authorHwang, Chung Su
dc.contributor.authorLee, Hyun Jung
dc.contributor.authorNa, Joo Young
dc.contributor.authorKim, Jee Yeon
dc.date.accessioned2023-03-07T09:19:13Z
dc.date.available2023-03-07T09:19:13Z
dc.date.issued2022
dc.description.abstractNeuroendocrine neoplasms (NENs) such as small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC) have characteristic histologies, but immunohistochemistry using neuroendocrine markers is still desirable to confirm diagnosis. CD56 is the most sensitive marker, but also stains various normal tissues and other tumors. Recently, we reported that nucleolar protein 4 (NOL4) is present in the blood of SCLC patients and found it was stained in the SCLC nuclei. In this study, we compared expressions of NOL4 and CD56, using 64 cases of SCLC, 18 cases of LCNEC, 6 cases of atypical carcinoid tumor, 7 cases of typical carcinoid tumor, 68 cases of lung adenocarcinoma, and 62 cases of lung squamous cell carcinoma. For primary lung NENs, sensitivity, specificity, positive predictive value (PPV) and negative predictive value of NOL4 were 77.5%, 95.8%, 93.2%, and 85.1%, respectively, while those of CD56 were 92.1%, 93.3%, 91.1%, and 94.1%. The specificity and PPV of NOL4 were higher than those of CD56, although the differences were not statistically significant. However, NOL4 retains its nuclear immunoreactivity in areas of crush artifact or necrosis. Furthermore, NOL4 was not expressed in adjacent normal tissues including bronchial cells and pneumocytes. Therefore, a combination of NOL4 staining with other cytoplasmic or membranous neuroendocrine markers might enhance diagnostic utility for SCLC and other NENs.es
dc.formatapplication/pdfes
dc.format.extent8es
dc.identifier.citationHistology and Histopathology Vol. 37, nº11 (2022)
dc.identifier.doihttps://doi.org/10.14670/HH-18-540
dc.identifier.issn0213-3911
dc.identifier.issn1699-5848
dc.identifier.urihttp://hdl.handle.net/10201/129127
dc.languageenges
dc.publisherUniversidad de Murcia, Departamento de Biologia Celular e Histiologiaes
dc.relationSin financiación externa a la Universidades
dc.rightsinfo:eu-repo/semantics/openAccesses
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectNeuroendocrinees
dc.subjectNOL4es
dc.subjectSmall cell lung canceres
dc.subjectBiomarkeres
dc.subject.otherCDU::6 - Ciencias aplicadas::61 - Medicina::616 - Patología. Medicina clínica. Oncologíaes
dc.titleNOL4 is a novel nuclear marker of small cell carcinoma and other neuroendocrine neoplasmses
dc.typeinfo:eu-repo/semantics/articlees
dspace.entity.typePublicationes
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Lee-37-1091-1098-2022.pdf
Size:
3.01 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.39 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Histology and histopathology Vol.37,nº11 (2022)